comparemela.com

DAEJEON,South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy. Under the terms of the agreement, PharmAbcine will sponsor a Phase I study in Australia to evaluate the safety and clinical efficacy of the combination therapy for the treatment of multiple advanced solid tumors, and MSD will supply KEYTRUDA. "We are excited to announce another pipeline combination project in collaboration with MSD besides olinvacimab, our lead anti-VEGFR2 antibody, undergoing a Phase II study in combination with KEYTRUDA in mTNBC (metastatic Triple Negative Breast Cancer) patients,"said Dr.Jin-San Yoo, CEO of PharmAbcine. "In preclinical studies, PMC-309 demonstrated significantly enhanced tumor growth reduction when used with an anti-PD-1 drug in in vivo mouse model compared to both monotherapies of PMC-309 and an anti-PD-1 drug.We look forward to the opportunity to investigate this approach in a clinical setting." Dr. Yoo also added, "In comparison to the existing immuno-oncology drugs that directly activate T cells, PMC-309's distinct mechanism of indirectly activating T cells by inhibiting immunosuppressive cells may represent a novel strategy for patients who do not respond well or have become resistant to the existing treatments and are in need of new therapies. "We are optimistic about PMC-309's best-in-class potential, and we are particularly excited to continue to evaluate it in combination with KEYTRUDA, one of the key leading molecules in cancer immunotherapy." Further details of agreement and clinical protocols were not disclosed. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,Rahway, NJ, USA. About PMC-309 PMC-309 is a novel IgG1 anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, an immune checkpoint receptor mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. In the nonclinical studies, it has been discovered that PMC-309 can promote both innate immunity (monocyte activation, M1 macrophage proliferation) and adaptive immunity (T cell activation) unlike the existing drugs which show significant changes only in adaptive immunity. In addition, the in vivo data showed that PMC-309 demonstrated significantly improved tumor growth inhibition when used in combination with an anti-PD-1 drug compared to both monotherapies of PMC-309 and an anti-PD-1 drug. These findings suggest that PMC-309 can offer a new treatment strategy in immuno-oncology area as it can be used in combination with other drugs to improve their low-response rates. The GLP-Toxicology studies were already completed, and no serious safety issues were observed. The Company plans to submit Clinical Trial Application in early 2023. About PharmAbcine Inc. PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. The Company's main pipeline assets include olinvacimab, the lead asset in clinical stage, and IND-ready preclinical assets with first-in-class potential such as PMC-309 and PMC-403. Olinvacimab, the Company's lead asset, is undergoing a Phase II trial in combination with MSD's pembrolizumab for mTNBC patients in Australia. The Company entered the Phase II study to reconfirm the encouraging result from Phase Ib olinvacimab-pembrolizumab trial, delivering 50% ORR, 67% DCR, and clean safety profile. PMC-309, a novel anti-VISTA-antagonizing IgG in pan pH, is an immune checkpoint regulator that targets MDSC (myeloid derived suppressor cells) and M2 macrophages which play pivotal role in maintaining immunosuppressive TME (Tumor Microenvironment). The Company plans to submit Clinical Trial Application for a Phase I study in late 2022. PMC-403 is a novel TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels and can be used for vascular-related eye disease, such as wet AMD (Age-related Macular Degeneration). The Company expects to submit an IND for a Phase I ophthalmology clinical trial in the second half of 2022. One of other early-stage assets, PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and can be applied to various modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell engager, and Radio-Immunotherapy For additional information about PharmAbcine, visit http://www.pharmabcine.comor follow on Youtubeand Linkedin. For licensing deals, joint venture, co-development, and collaboration in research or antibody discovery inquiries, please contact: Business Development Team E-mail: bd@pharmabcine.com Office line: +82 70 4279 5100 For investor relations and public relations inquiries, please contact: IR/PR Team Sungjun Park, Associate E-mail: sungjun.park@pharmabcine.com Office line: +82 70 4270 2637

Related Keywords

Australia ,United States ,Daejeon ,Taejon Gwangyoksi ,South Korea ,Jin San Yoo ,Linkedin ,Business Development Team ,Ir Pr Team ,Pharmabcine Inc ,Merck Co Inc ,Youtube ,Merck Sharp Dohme ,Prnewswire Pharmabcine Inc ,Triple Negative Breast Cancer ,Merck Sharp ,V Domain Ig Suppressor ,Myeloid Derived Suppressor Cells ,Clinical Trial Application ,Tumor Microenvironment ,Age Related Macular Degeneration ,Dec 12 ,022 Prnewswire Pharmabcine Inc Kosdaq 208340ks ,A Clinical Stage Biotech Company Focusing On The Development Of Next Generation Antibody Therapeutics ,Nnounced Today That The Company Has Entered Intoa Clinical Collaboration Agreement With Msd Merck Amp Co ,Nc ,Rahway ,J ,Sa ,O Initiatea Phasei Combination Trial Of Pmc 309 ,A Novel Anti Vistav Domain Ig Suppressor Oft Cell Activation Antibody ,N Combination With Keytruda Pembrolizumab ,Sd 39s Anti Pd 1 Therapy Under The Terms Of Agreement ,Harmabcine Will Sponsora Phasei Study In Australia To Evaluate The Safety And Clinical Efficacy Of Combination Therapy For Treatment Multiple Advanced Solid Tumors ,Nd Msd Will Supply Keytruda Quot We Are Excited To Announce Another Pipeline Combination Project In Collaboration With Besides Olinvacimab ,Ur Lead Anti Vegfr2 Antibody ,Ndergoinga Phase Ii Study In Combination With Keytruda Mtnbc Metastatic Triple Negative Breast Cancer Patients ,Uot Said Dr Jin San Yoo ,Eo Of Pharmabcine Quot In Preclinical Studies ,Mc 309 Demonstrated Significantly Enhanced Tumor Growth Reduction When Used With An Anti Pd 1 Drug In Vivo Mouse Model Compared To Both Monotherapies Of Pmc And We Look Forward The Opportunity Investigate This Approach Ina Clinical Setting Quot Dr Yoo Also Added ,Uot In Comparison To The Existing Immuno Oncology Drugs That Directly Activatet Cells ,Mc 309 39s Distinct Mechanism Of Indirectly Activatingt Cells By Inhibiting Immunosuppressive May Representa Novel Strategy For Patients Who Do Not Respond Well Or Have Become Resistant To The Existing Treatments And Are In Need New Therapies Quot We Optimistic About Pmc Best Class Potential ,Nd We Are Particularly Excited To Continue Evaluate It In Combination With Keytruda ,Ne Of The Key Leading Molecules In Cancer Immunotherapy Quot Further Details Agreement And Clinical Protocols Were Not Disclosed Keytruda Isa Registered Trademark Merck Sharp Amp Dohme Llc ,A Subsidiary Of Merck Amp Co ,Sa About Pmc 309 Isa Novel Igg1 Anti Vistav Domain Ig Suppressor Oft Cell Activation Antagonizing Antibody That Can Be Used For The Treatment Of Various Tumor Types By Inhibiting Vista ,N Immune Checkpoint Receptor Mainly Expressed On Mdsc Myeloid Derived Suppressor Cells And Tregs Regulatoryt ,T Can Playa Pivotal Role In Maintaining The Immunosuppressive Environment Around Tumor Cells Nonclinical Studies ,T Has Been Discovered That Pmc 309 Can Promote Both Innate Immunity Monocyte Activation ,1 Macrophage Proliferation And Adaptive Immunityt Cell Activation Unlike The Existing Drugs Which Show Significant Changes Only In Immunity Addition ,He In Vivo Data Showed That Pmc 309 Demonstrated Significantly Improved Tumor Growth Inhibition When Used Combination With An Anti Pd 1 Drug Compared To Both Monotherapies Of And These Findings Suggest Can Offera New Treatment Strategy Immuno Oncology Area As It Be Other Drugs Improve Their Low Response Rates The Glp Toxicology Studies Were Already Completed ,Nd No Serious Safety Issues Were Observed The Company Plans To Submit Clinical Trial Application In Early 2023 About Pharmabcine Inc Isa Stage Public Developing Next Generation Igg Based Therapeutics Treat Cancer ,Eovascular Eye Diseases ,Nd Vascular Related Unmet Needs The Company 39s Main Pipeline Assets Include Olinvacimab ,He Lead Asset In Clinical Stage ,Nd Ind Ready Preclinical Assets With First In Class Potential Such As Pmc 309 And 403 Olinvacimab ,He Company 39s Lead Asset ,S Undergoinga Phase Ii Trial In Combination With Msd 39s Pembrolizumab For Mtnbc Patients Australia The Company Entered Study To Reconfirm Encouraging Result From Ib Olinvacimab ,Elivering 50 Orr ,7 Dcr ,Nd Clean Safety Profile Pmc 309 ,A Novel Anti Vista Antagonizing Igg In Pan Ph ,S An Immune Checkpoint Regulator That Targets Mdsc Myeloid Derived Suppressor Cells And M2 Macrophages Which Play Pivotal Role In Maintaining Immunosuppressive Tme Tumor Microenvironment The Company Plans To Submit Clinical Trial Application Fora Phasei Study Late 2022 Pmc 403 Isa Novel Tie2 Activating Antibody Stabilizes Dysfunctional Leaky Disorganized Pathological Vessels Can Be Used For Vascular Related Eye Disease ,Uch As Wet Amd Age Related Macular Degeneration The Company Expects To Submit An Ind Fora Phasei Ophthalmology Clinical Trial In Second Half Of 2022 One Other Early Stage Assets ,Mc 005 ,S An Anti Egfrviii Igg That Only Binds To Expressed On Cancer Cells And Can Be Applied Various Modalities Including Car T ,Car Nk ,Ar Macrophage ,T Cell Nk Engager ,Nd Radio Immunotherapy For Additional Information About Pharmabcine ,Isit Http Www Pharmabcine Comor Follow On Youtubeand Linkedin For Licensing Deals ,Joint Venture ,Edo Development ,Nd Collaboration In Research Or Antibody Discovery Inquiries ,Lease Contact Business Development Teame Mail Bd Pharmabcine Com Office Line 82 70 4279 5100 For Investor Relations And Public Inquiries ,Lease Contact Ir Pr Team Sungjun Park ,Ssociatee Mail Sungjun Park Pharmabcine Com Office Line 82 70 4270 2637 ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.